RT Journal Article
SR Electronic
T1 Breastmilk; a source of SARS-CoV-2 specific IgA antibodies
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.18.20176743
DO 10.1101/2020.08.18.20176743
A1 Britt J. van Keulen
A1 Michelle Romijn
A1 Albert Bondt
A1 Kelly A. Dingess
A1 Eva Kontopodi
A1 Karlijn van der Straten
A1 Maurits A. den Boer
A1 Berend J. Bosch
A1 Philip J.M. Brouwer
A1 Christianne J.M. de Groot
A1 Max Hoek
A1 Wentao Li
A1 Dasja Pajkrt
A1 Rogier W. Sanders
A1 Anne Schoonderwoerd
A1 Sem Tamara
A1 Rian A.H. Timmermans
A1 Gestur Vidarsson
A1 Koert J. Stittelaar
A1 Theo T. Rispens
A1 Kasper A. Hettinga
A1 Marit J. van Gils
A1 Albert J.R. Heck
A1 Johannes B. van Goudoever
YR 2020
UL http://medrxiv.org/content/early/2020/08/21/2020.08.18.20176743.abstract
AB Background Since the outbreak of COVID-19, many put their hopes in the rapid development of effective immunizations. For now patient isolation, physical distancing and good hygiene are the sole measures for prevention. Processed breast milk with antibodies against SaRS-CoV-2 may serve as additional protection. We aimed to determine the presence and neutralization capacity of antibodies against SaRS-CoV-2 in breastmilk of mothers who have recovered from COVID-19.Methods This prospective case control study included lactating mothers, recovered from (suspected) COVID-19 and healthy controls. Serum and breastmilk was collected. To assess the presence of antibodies in breastmilk and serum, we used multiple complementary assays, namely ELISA with the SARS-CoV-2 spike protein, SARS-CoV-2 receptor binding domain (RBD) and with the SARS-CoV-2 nucleocapsid (N) protein for IgG and bridging ELISA with the SARS-CoV-2 RBD and N protein for total Ig. To assess the effect of pasteurization breastmilk was exposed to Holder Pasteurization and High Pressure Pasteurization.Results Breastmilk contained antibodies against SARS-CoV-2 using any of the assays in 24 out of 29 (83%) proven cases, in six out of nine (67%) suspected cases and in none of the 13 controls. In vitro neutralization of SARS-CoV-2 clinical isolate virus strain was successful in a subset of serum (13%) and milk samples (26%). Although after pasteurization of the milk SARS-CoV-2 antibodies were detected with both methods of pasteurization, virus neutralizing capacity of those antibodies was only retained with the HPP approach.Conclusion Breastmilk of mothers who recovered from COVID-19 contains significant amounts of IgA against SARS-CoV-2, both before and after pasteurization.Question Does breastmilk of mothers who have recovered from coronavirus disease 2019 (COVID-19) contain antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)?Findings We provide multiple lines of evidence on the presence of a variety of antibodies against SARS-CoV-2, with no such antibodies present in the controls. These antibodies are capable of neutralizing a clinical isolate of SARS-CoV-2 in vitro. We furthermore show that high pressure pasteurization hardly affects antibody levels and efficacy.Meaning Breastmilk, obtained from mothers who have recovered from COVID-19, may serve as a safe and widely applicable preventive strategy for vulnerable high risk populationsCompeting Interest StatementThe authors have declared no competing interest.Funding StatementThe study was funded by de Stichting Steun Emma Kinderziekenhuis. No payment by a pharmaceutical company or other agency was made.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:For this study approval of the Ethical Committe of the VUmc was obtained, approval number 2020.199.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors confirm that the data supporting the findings of this study are available within the article [and/or] its supplementary materials. The data that support the findings of this study are available from the corresponding author upon reasonable request.